Otros idiomas Fulcrum Therapeutics, Inc.

Acciones

FULC

US3596161097

Tiempo real estimado Cboe BZX Otros sitios de cotización 17:36:01 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
7,03 ^USD	-0,71 %		-4,84 %	+4,89 %

18/03	Fulcrum Therapeutics nombra a Patrick Horn director médico	MT
18/03	Fulcrum Therapeutics, Inc. anuncia cambios ejecutivos	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium	28/03
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	25/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/03
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics, Inc. Announces Executive Changes	18/03
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	18/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference	05/03
GSK : la Dr Jeannie Lee entre au conseil d'administration	29/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	28/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET	20/02
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	08/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Fulcrum Therapeutics, Inc.

Acciones

FULC

US3596161097

Otros idiomas

Filtros